La Jolla, CANCT06639724Now EnrollingIRB Ready

Pancreatic Ductal Adenocarcinoma (PDAC) Clinical Trial in La Jolla, CA

Access cutting-edge pancreatic ductal adenocarcinoma (pdac) treatment through this phase 1 clinical trial at a research site in La Jolla. Study-provided care at no cost to qualified participants.

Sponsored by University of California, San Diego

Quick Self-Assessment

See if you qualify for this La Jolla location

Preparing your pre-screening questions…

Expert Care in La Jolla

Access pancreatic ductal adenocarcinoma (pdac) specialists at no cost

IRB Approved

This study follows strict safety protocols and ethical guidelines

No-Cost Care

All study-related pancreatic ductal adenocarcinoma (pdac) treatment provided free

Apply for This La Jolla Location

Check if you qualify for this pancreatic ductal adenocarcinoma (pdac) clinical trial in La Jolla, CA

Secure & Confidential

Your information is protected and will only be shared with the research team.

Why Participate?

  • No-Cost Study Care

  • Local to La Jolla

    Convenient for CA residents

  • Cutting-Edge Treatment

    Access to innovative therapies

  • Expert Medical Care

    Close monitoring by specialists

  • Possible Compensation*

    For time and travel

*Compensation varies by study. Confirm details with coordinator.

Simple Process

  1. 1Submit this form
  2. 2Phone screening
  3. 3Visit La Jolla site if eligible
  4. 4Begin participation

About This Pancreatic Ductal Adenocarcinoma (PDAC) Study in La Jolla

This is a Phase 1b trial evaluating the combination of Fostamatinib, a Syk kinase inhibitor currently FDA-approved for chronic idiopathic thrombocytopenia purpura (ITP), with the standard of care chemotherapy agents gemcitabine and nab-paclitaxel, for the perioperative treatment of resectable non metastatic pancreatic ductal adenocarcinoma (PDAC).

Sponsor: University of California, San Diego

Who Can Participate

Inclusion Criteria

Patient has the ability to understand and willingness to sign a written informed consent.
Patient is ≥ 18 years of age.
Eastern Cooperative Oncology Group (ECOG) Performance Status ≤ 1.
Patient must have surgical consult to verify patient is a surgical candidate within 28 days prior to enrollment.
Patient must have resectable primary PDAC based on contrast-enhanced CT or MRI of the chest, abdomen, and pelvis performed no more than 4 weeks before enrollment/baseline. Note that if CT or MRI was performed more than 4 weeks before this visit, imaging needs to be repeated to evaluate eligibility in the study. Resectable primary tumor is defined as:
No involvement of the celiac artery, common hepatic artery, and superior mesenteric artery (and, if present, replaced right hepatic artery).
No involvement, or \< 180° interface between tumor and vessel wall, of the portal vein and/or superior mesenteric vein.
Patent portal vein/splenic vein confluence.
No evidence of metastatic disease.
Lymphadenopathy (defined as nodes measuring \> 1cm in short axis) outside the surgical basin (i.e., para- aortic, peri-caval, celiac axis, or distant nodes) is considered M1 disease and makes the patient ineligible. If, however, such nodes are biopsied and are negative, then enrollment can be considered after review with the study principal investigator (PI) and/or co-investigator.
For tumors of the body and tail of the pancreas, involvement of the splenic artery and vein of any degree is considered resectable disease.
Patient has adequate organ function as defined below:
Absolute Neutrophil Count ≥ 1.5 x 10\^9/L
Platelet count ≥ 100 x 10\^9/L.
Hemoglobin ≥ 9.0 g/dL
aspartate aminotransferase (AST/SGOT) and alanine aminotransferase (ALT/SPGT) ≤ 2.5 X institutional upper limit of normal (ULN)
Total Bilirubin ≤ 1.5 x institutional ULN or ≤3 × institutional ULN in Gilbert's Ds
Serum creatinine ≤ 2 x institutional ULN
For subjects able to become pregnant: use of highly effective contraception for at least 2 weeks prior to enrollment and agreement to use such a method during study participation.
For subjects able to cause a pregnancy: use of condoms or other methods to ensure effective contraception with partner during study participation.

Exclusion Criteria

Any prior treatment for PDAC.
Recurrent or metastatic PDAC.
Peripheral neuropathy \> grade 2
Received an investigational agent within 28 days prior to the first dose of study drug.
History of Hepatitis B (defined as Hepatitis B surface antigen, HBsAg, reactive) or known active Hepatitis C virus (HCV) (defined as HCV RNA - qualitative - is detected) infection. Note: no testing for Hepatitis B and Hepatitis C is required unless mandated by local health authority. (Individuals who are hepatitis C antibody positive may be enrolled if negative viral load confirmed).
Active infection requiring systemic therapy.
Known psychiatric or substance abuse disorders that would interfere with cooperation with the requirements of the trial.
History of receiving a solid organ transplant or allogeneic bone marrow transplant.
Major surgical procedure within 28 days prior to the first dose of study drug.
Unable or unwilling to withhold or discontinue any prohibited or restricted medications/procedures for the specified windows during the study.
Pregnancy or lactation.

Not sure if you qualify? Submit your interest and a study coordinator will help determine your eligibility.

Frequently Asked Questions

Q:Is this study available in La Jolla?

Yes, this clinical trial (NCT06639724) has an active research site in La Jolla, CA that is currently enrolling participants.

Q:Is it safe to participate?

Clinical trials follow strict safety guidelines and ethical standards. This study has been reviewed and approved, and participants are closely monitored by medical professionals. You can withdraw at any time.

Q:Will I be compensated?

Many clinical trials offer compensation for your time and travel expenses. Specific compensation details will be discussed during the screening process. All study-related medical care is provided at no cost.

Q:Can I leave the trial if I change my mind?

Absolutely. Participation is completely voluntary. You have the right to withdraw from the study at any time, for any reason, without penalty.

Still have questions? Our study coordinators are here to help.

Pancreatic Ductal Adenocarcinoma (PDAC) Treatment Options in La Jolla, CA

If you're searching for pancreatic ductal adenocarcinoma (pdac) treatment options in La Jolla, CA, this clinical trial (NCT06639724) may be an excellent opportunity. Clinical trials provide access to cutting-edge treatments that aren't yet available to the general public, often at no cost to participants.

Our La Jolla research site is actively enrolling participants for this phase 1 clinical trial. You'll receive care from experienced pancreatic ductal adenocarcinoma (pdac) specialists who are at the forefront of medical research. All study-related care, including examinations, treatments, and monitoring, is provided at no cost to qualified participants.

Looking for more options? Browse all pancreatic ductal adenocarcinoma (pdac) clinical trials near you to find additional studies recruiting in your area.

More Pancreatic Cancer Trials in La Jolla, CA

See all pancreatic cancer clinical trials recruiting in La Jolla — not just this study.

Browse Pancreatic Cancer Trials in La Jolla →

Browse More Trials by Condition

Pancreatic Cancer TrialsAlzheimers Disease TrialsParkinsons Disease TrialsUlcerative Colitis TrialsAtopic Dermatitis TrialsInterstitial Cystitis TrialsAll Conditions →

Ready to Join in La Jolla?

Take the first step toward participating in this groundbreaking clinical trial

Secure · Expert Care · La Jolla, CA